- Home
- OIM vs XFOR Comparison
OIM vs XFOR Comparison
Compare OIM & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIM | XFOR |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.0M | 377.3M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | OIM | XFOR |
|---|---|---|
| Price | $10.11 | $4.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 75.0K | ★ 1.0M |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $1.35 |
| 52 Week High | $10.33 | $4.83 |
Technical Indicators
Market Signals| Indicator | OIM | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 57.23 |
| Support Level | N/A | $3.50 |
| Resistance Level | $10.33 | $4.41 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 27.12 | 60.47 |
Price Performance
Historical ComparisonAbout OIM OneIM Acquisition Corp. Class A Ordinary Shares
OneIM Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.